Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Notice of Results

30 Apr 2024 07:00

RNS Number : 4922M
Cambridge Cognition Holdings PLC
30 April 2024
 

 

30 April 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Notice of Results

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, will announce its Preliminary Results for the year ended 31 December 2023 on Wednesday 1 May 2024.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc 

Matthew Stork, Chief Executive Officer 

Stephen Symonds, Chief Financial Officer 

Tel: 012 2381 0700 

 

 

Panmure Gordon (UK) Limited (NOMAD and Joint Broker) 

Freddy Crossley / Emma Earl  

Rupert Dearden 

 

Tel: 020 7886 2968 

(Corporate Finance) 

(Corporate Broking) 

 

Dowgate Capital Limited (Joint Broker) 

David Poutney / James Serjeant 

 

Tel: 020 3903 7715 

 

 

Hudson Sandler (Financial PR and IR) 

Dan de Belder / Hattie Dreyfus 

 

Tel: 020 7796 4133 

cog@hudsonsandler.com

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit: https://cambridgecognition.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORBIGDSUUDDGSC

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.